Hospenthal D R, Byrd J C, Weiss R B
Department of Medicine, Walter Reed Army Medical Center, Washington, DC., USA.
Med Pediatr Oncol. 1995 Aug;25(2):119-22. doi: 10.1002/mpo.2950250214.
Herein we report the successful treatment of invasive aspergillosis with the liposomal amphotericin B (AMB) formulation, Amphotericin B Lipid Complex (ABLC). This investigational compound was employed in a 50-year-old patient with acute myelomonocytic leukemia complicated by prolonged, treatment-induced granulocytopenia and documented Aspergillus flavus sinusitis with signs of disseminated aspergillosis. The patient demonstrated radiographic signs of pulmonary aspergillosis and biochemical signs of hepatic involvement that were resistant to a 23 day course of conventional AMB (Fungizone) therapy. Following therapy with ABLC her fever abated, her chest X-ray findings improved, and her hepatic function tests improved with eventual resolution.
在此,我们报告用脂质体两性霉素B(AMB)制剂两性霉素B脂质复合物(ABLC)成功治疗侵袭性曲霉病的病例。该研究用化合物用于一名50岁的急性粒单核细胞白血病患者,该患者并发长期治疗引起的粒细胞减少症,并有记录显示患有黄曲霉鼻窦炎且有播散性曲霉病的迹象。患者表现出肺曲霉病的影像学征象和肝脏受累的生化征象,对常规AMB(两性霉素B)治疗23天疗程耐药。用ABLC治疗后,她的发热消退,胸部X线检查结果改善,肝功能检查改善,最终病情得到缓解。